Chelation therapy is a mainstream treatment used to treat heavy metal poisoning. Ethylene diamine tetraacetic acid (EDTA) has been approved by the U.S. Food and Drug Administration (FDA) as a treatment for lead poisoning. EDTA is a synthetic amino acid that binds, or chelates, heavy metals, including lead, mercury, and cadmium to reduce atherosclerotic plaque and other mineral deposits throughout the cardiovascular system. 

The human body cannot break down heavy metals, which can build up to toxic levels in the body and interfere with normal functioning. EDTA and other chelating drugs lower the blood levels of metals by attaching to the heavy metal molecules, which helps the body remove them through the urine. 

Chelation therapy has been used safely and successfully for more than fifty years as an alternative treatment for many conditions, such as: circulatory disorders (coronary artery, peripheral artery and cerebrovascular disease), diabetes related disorders of the circulatory and nervous systems, dementias such as Alzheimer’s, COPD and emphysema, auto-immune disorders such as: psoriasis, rheumatoid arthritis, lupus. It has also been successfully used in cases of macular degeneration with improvement of sight.*

If it is determined that you may benefit from chelation treatments, the Center administers EDTA through a vein over a period of three to four hours. A typical treatment cycle may include twenty infusions over ten to twelve weeks.

*Disclaimer: Individual results may vary and are not guaranteed.